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INTRODUCTION
Transforming growth factor- (TGF- ) family consists of
a large number of structurally related polypeptide growth fac-
tors that have a crucial role in the regulation of cellular pro-
cesses, such as cell division, differentiation, lineage determi-
nation, motility, adhesion, and apoptosis (1). Smads, small
families of structurally related proteins, are signal transducers
for the members of the TGF- superfamily (1). They are
molecules of relative molecular mass ranging from 42 kDa to
60 kDa with two regions of homology at the amino and car-
boxy terminals called the Mad-homology domains, abbrevi-
ated to MH1 and MH2, respectively, and connected together
by a proline-rich linker sequence (2). Different members of the
Smad family have different roles in TGF- signaling. Smad2
and Smad3 are activated via carboxy-terminal phosphoryla-
tion by TGF- Receptor Type-1 (TGR1) kinases. They form
heterotrimeric complexes with Smad4, and thereby act in a
pathway- restricted fashion (3). Smad2 and Smad3 are also
called receptor- activated Smads. Smad4-receptor-activator
Smads complexes then translocates into the nucleus and act
as a TGF- - induced transcriptional activator of target genes
(4). So Smad4 is a central mediator of Smad function (5). In
contrast, Smad6 and Smad7 function as inhibitors of TGF-
signaling. They bind to TGR1 and interfere with the phos-
phorylation of the receptor-activated Smads. Consequently,
active heterotrimeric Smad complexes are not formed (6, 7).
Smad6 preferentially inhibits bone morphogenetic protein
(BMP) signaling and Smad7 inhibits TGF- signaling (8-10).
Moreover, because of the importance of the role of TGF- in
the regulation of fundamental cell homeostatic processes, it
is not surprising that tumor cells from different origins are
either partially or completely resistant to the anti-proliferative
effect of TGF- (11, 12). Although, alterations in the func-
tion and expression of TGF- -receptors have been shown to
contribute to the resistance to the antiproliferative effects of
TGF- in cancer (13), little is known comparatively about the
qualitative or quantitative alterations of Smads within the
TGF- pathway in cancer, especially hepatocarcinogenesis.
Experimental hepatocarcinogenesis in rats occurs in distinctly
defined stages: initiation, promotion, and progression. The
resistant hepatocyte model developed by Solt and Farber has
been widely used for studying multistep chemical hepatocar-
cinogenesis (14, 15). Clonal expansion of genetically altered
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Expression and Localization of the Transforming Growth Factor-
Type I receptor and Smads in Preneoplastic Lesions during Chemical
Hepatocarcinogenesis in Rats
Little is known about the involvement of Smad-related molecules in the regulation
of the Transforming Growth Factor (TGF)- signaling pathway during hepatocar-
cinogenesis, particularly with respect to preneoplastic lesions of a rat liver. The
aims of this study were to investigate the localizations and temporal expressions of
TGF- Receptor Type 1 (TGR1) and Smads during the promotion stage of chemi-
cal hepatocarcinogenesis in rats. We investigated expressions and localizations
of TGR1, Smad2, Smad4, and Smad7 by using semi-quantitative RT-PCR and
immunohistochemistry in preneoplastic lesions during rat chemical hepatocarcino-
genesis induced by Solt and Farber’s method. The down-regulation of TGR1, Sma-
d2, and Smad4 was evident during the later steps of the promotion stage of chem-
ical hepatocarcinogenesis. In contrast with other Smads, increased Smad7 expres-
sion was evident during the later steps of the promotion stage. Also immunohisto-
chemistry revealed that the main site of TGR1, Smad2, Smad4, and Smad7 expre-
ssion was mainly in hepatocytes of the preneoplastic lesions of a rat liver. Dysreg-
ulation of the downstream effectors of TGF- such as TGR1, Smad2, Smad4 and,
Smad7 might contribute to the progression of preneoplastic lesions during chemical
hepatocarcinogenesis in a rat.
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preneoplastic hepatocytes occurs during the stage of promo-
tion. This expansion is caused by a selective increase in cell
proliferation and a decrease in the apoptosis of genetically
altered hepatocytes of initiation stage. However, the exact bio-
logical characteristics of preneoplastic lesions of the rat liver
are still unclear concerning TGF- signaling. Also the tem-
poral expression and cellular localization of TGR1 and of Smads
in chemical hepatocarcinogenesis are not clearly elucidated,
especially in the promotion stage of rat chemical hepatocar-
cinogenesis. Therefore, we undertook this study to investigate
the expressions and localizations of TGR1, Smad2, Smad4,
and Smad7 by using semi-quantitative RT-PCR, immuno-
histochemistry during the promotion stage of chemical hep-
atocarcinogenesis in the rat.
MATERIALS AND METHODS
Induction of Chemical Hepatocarcinogenesis
Male Sprague-Dawley rats, weighing 200 g, were maintained
on standard pelleted chow and had access to water ad libitum.
Solt and Farber’s method was used to induce hepatocarcino-
genesis. Briefly, rats were initiated with a single dose (200
mg/kg) of Diethylnitrosamine (DEN), (Sigma Chemical Co.
St. Louis, MO, U.S.A.), administered intraperitoneally by injec-
tion. Two weeks after the initiation, all rats received a daily oral
gavage of 10 mg/kg 2-actetylaminofluorene (2-AAF Sigma),
for a period of up to 14 days. A partial hepatectomy was per-
formed 1 week after the 2-AAF treatment. Three animals were
sacrificed, as indicated, on 1, 3, 7, 14, 28, 42, and 56 days
after the initiation of the partial hepatectomy. A sham oper-
ation was performed in the age-matched controls, which did
not receive the AAF/DEN treatment. After gross examination
of the sample, a portion of each sample was fixed in a 10%
neutrally buffered formalin solution and routinely processed
for hematoxylin and eosin staining and immunohistochem-
ical staining. We examined morphological features of preneo-
plastic lesions (altered cellular foci and hyperplastic nodule)
based on previous report (16). The remainder of each sample
was frozen in liquid nitrogen and kept at 70℃prior to RNA
isolation. All experiments were conducted in accordance with
the guidelines of the institutional review committee at Pusan
National University School of Medicine.
RNA Extraction and Semi-quantitative RT-PCR
Total RNA was isolated from freshly frozen tissue using
an RNeasy Kit (Qiagen, Santa Clarita, CA, U.S.A.). cDNA
was synthesized from 5  g of total RNA using 2  g of ran-
dom hexamer (Pharmacia, Uppsala, Sweden), 10 mM dNTP
(Boehringer Mannheim, Mannheim, Germany) and 200 U of
M-MLV reverse transcriptase (GIBCO BRL) in a final volume
of 25  L. PCR was performed by using 1.25 mM of dNTP,
0.25 U of Taq polymerase (Perkin Elmer, Branchburg, NJ,
U.S.A.), 10 pmol of primer pairs compatible with rat TGR1,
Smad2, Smad4, Smad7, GST-P, and GAPDH as an internal
control, and cDNA using a thermal cycler (Perkin Elmer,
Branchburg, NJ, U.S.A.). The sequences, reaction conditions,
number of cycles, and the size of product for each of the primer
pairs used in this study are summarized in Table 1. The PCR
cycling conditions used were: denaturation at 94℃for 1 min,
annealing at 55-60℃for 1 min, extension at 72℃for 1 min,
and with a final extension at 72℃for 10 min. PCR products
were analyzed in a 1.5% agarose gel stained with ethidium
bromide. The optical density of each band was measured by
using a geldocumentation device (Gel Doc 1000, Bio-Rad
Laboratories, CA, U.S.A.). Densitometric analysis was used to
determine the optical density ratios of TGR1, Smad2, Smad4,
Smad7, GST-P versus GAPDH.
Immunohistochemical Staining 
Sections were dewaxed and rehydrated according to a stan-
dard procedure, and washed with PBS. For immunohistoche-
mical staining, sections were heated in a microwave oven at
600W for 2 times of 7 min and for 5 min in 0.01M citrate
buffer (pH 6.0). Sections were then immersed in 3% H2O2
to quench endogenous peroxidase activity, and unspecified
binding was blocked in 5% normal goat serum (0.1% BSA
Primers Product size (bp) No. of cycle Annealing temp (℃) Sequences
Table 1. Primer sequences of TGR1, Smad2, Smad4, Smad7, GST-P, and GAPDH used in the present study
TGR1 5′ -GCGAATTCTTCAGAAAAGCAGTCAGCTG-3′ 57 25 318
5′ -GCCTCGAGAACTTCTCCAAACCGACCTT-3′
Smad2 5′ -CGATGCTCAAGCATGTCCTA-3′ 60 26 124
5′ -CGCTCTGGGTTTTGACTAGC-3′
Smad4 5′ -GTTGCAGATAGCTTCAGGGC-3′ 60 26 357
5′ -GGATCCACGTATCCATCCAC-3′
Smad7 5′ -CCAACTGCAGACTGTCCAGA-3′ 60 27 106
5′ -CAGGCTCCAGAAGAAGTTGG-3′
GST-P 5′ -AAGTTTGAAGATGGAGACCT-3′ 55 25 167
5′ -GATAGTTAGTGTAGATGAGGG-3′
GAPDH 5′ -ACCACAGTCCATGCCATCAC-3′ 57 25 452
5′ -CCACCACCCTGTTGCTGTA-3′512 D.Y. Park, C.H. Lee, M.Y. Sol, et al.
in PBS) or 5% normal rabbit serum (0.1% BSA in PBS). Im-
munohistochemical staining was performed by the avidin-bi-
otin peroxidase complex method with aminoethylcarbazole as
a chromogen, using the Vectastain ABC elite kit (Vector Lab-
oratories, Burlingame, CA, U.S.A.) according to the manufac-
turer’s instructions. Sections were counterstained with Mayer’s
hematoxylin solution. To detect TGR1, Smad2, Smad4, Smad-
7 and GST-P, we used polyclonal antibodies against TGR1
(rabbit IgG, sc-398, Santa-Cruz, CA, U.S.A.), Smad2 (goat
IgG, sc-6200, Santa-Cruz), Smad4 (goat IgG, sc-1909), Smad7
(goat IgG, sc-7004), and GST-P (311, MBL, Nagoya, Japan)
were used at a dilution of 1:100, 1:50, 1:50, 1:100, and 1:
1,000, respectively. Control experiments included incubation
of the sections with normal rabbit or goat IgG or primary anti-
bodies neutralized with an excess of blocking peptide, respec-
tively.
Sequential Quantification of GST-P-positive Lesions
The expression of glutathione S-transferase placental form
(GST-P) in focal areas of hepatocytes has been widely used as
a marker to identify preneoplastic lesions in the rat liver (17).
Areas of GST-P-positive lesions were measured by using a color
image processor (Image Pro-plus, Mediacybernetics, Maryland,
U.S.A.) and results are expressed in mm2 of stained area per
cm2. Mean and standard deviation of the areas of GST-P-pos-
itive lesions per animal, for each area chosen, were used to gen-
erate the results shown in Fig. 1.
Detection of Apoptotic Cells
Cells undergoing programmed cell death (apoptosis) were
detected in situ by specifically labeling nuclear DNA fragmen-
tation (TUNEL method), using ApopTag in situ detection
kit/peroxidase (Intergen, Purchae, NY, U.S.A.), in accordance
with the manufacturer’s instructions for the detection of apop-
totic cells.
Statistical Analysis
TGR1, Smad2, Smad4, and Smad7 positive cells under the
light microscope at 400X were counted and expressed as a per-
centage of total nuclei counted, involving 1000 nuclei per ani-
mal in randomly selected preneoplastic lesions (including al-
tered cellular foci and hyperplastic nodules) of rat liver. The
number of TUNEL-positive apoptotic cells was counted in
randomly selected preneoplastic lesions and adjacent liver pa-
renchyme, respectively as same method. The results are exp-
ressed as means±standard deviation (SD). The Kruskal-Wallis
test was used for the statistical analysis. Significance was de-
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Fig. 1. Sequential changes in GST-P- (+) preneoplastic areas. Se-
quential changes in GST-P- (+) altered hepatocytes (A) 3 days after
partial hepatectomy (PH), hyperplastic nodule (B) 14 days after
PH, and the areas of GST-P- (+) lesions per unit area (mm2/cm2)
rapidly increased with time (C). Magnification ×100. The values
shown represent mean±SD. S indicates sham operated control
liver.Smads in Preneoplastics Lesion of Rat Liver 513
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Fig. 2. Semi-quantitative RT-PCR analysis shows the early increase of Smad2, Smad4, and TGR1 transcripts and a significant decrease
in later steps of promotion (42 days after partial hepatectomy). Transcripts of Smad7 are more strongly expressed throughout the promo-
tion stage than in sham operated control livers. There was no decrease of Smad7 transcripts during the later steps of the promotion stage.
A significant increase in the GST-P transcripts is also noted (A). Densitometric analysis of semi-quantitative RT-PCR was used to obtain
the relative of optical densities of Smad2 (■), Smad4 (▲), TGR1 (●), and Smad7 (◆) versus GAPDH (B). The figures represent three
independent samples. The values shown are mean±SD. S indicates the sham operated control liver.
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Fig. 3. Immunohistochemical staining for TGR1. Some TGR1-positive cells are observed in altered cellular foci (A) 7 days after partial hepa-
tectomy (PH), and an increased number of positive cells are noted in hyperplastic nodules (B) at 28 days after PH. Loss of the expression
of TGR1 in hyperplastic nodules (C) at 42 days after PH is observed. TGR1 expression is noted in the cytoplasm of hepatocytes without lin-
ear reinforcement (D). Magnification at×100 for A, B and C, and at×200 for D.514 D.Y. Park, C.H. Lee, M.Y. Sol, et al.
fined as p<0.05.
RESULTS
Sequential Quantification of GST-P-positive Cells in
Preneoplastic Lesions of Rat Liver
The histopathological findings of the chemical hepatocar-
cinogenesis induced by Solt and Farber’s method resembled
those described previously (14, 15). In brief, 1 month after
partial hepatectomy, variable numbers of preneoplastic lesions
(clear cell foci, basophilic foci, eosinophilic foci and hyperplas-
tic nodules) were apparent. An increase in the number of hyper-
plastic nodules was observed with time. Because the expres-
sion of GST-P in focal areas of hepatocytes has been widely
used as a marker to identify preneoplastic lesions in the rat
liver (16), we performed semi-quantitative RT-PCR and
immunohistochemistry for GST-P. Fig. 1 and Fig. 2A show
that GST-P-positive preneoplastic lesions rapidly increased
with time and this was related to the progression of preneo-
plastic lesions during chemical hepatocarcinogenesis.
Expression of TGR1, and Smads Transcripts in Pre-
neoplastic Lesions of Rat Liver
To verify the temporal expressions of TGR1, Smad2, Smad4,
and Smad7 transcripts in the promotion stage of chemical he-
patocarcinogenesis, semi-quantitative RT-PCR was performed
in each liver sample on 1, 3, 7, 14, 28, 42, and 56 days after
partial hepatectomy. Fig. 2 showed that TGR1 transcripts were
increased during the early promotion stage and peaked at 28
days after partial hepatectomy. However, TGR1 was decreased
with time, especially during the later stage of the promotion
(42 days after partial hepatectomy). The transcripts of Smad2
and Smad4 were increased during the early steps of the pro-
motion stage and peaked at 14 and 7 days after partial hep-
atectomy, respectively. Thereafter, Smad2, and Smad4 were
decreased with time (Fig. 2). Sham-operated control liver also
showed lower levels of the of TGR1, Smad2, and Smad4 tran-
scripts. In contrast to the other transcripts, Smad7 transcripts
were more strongly expressed throughout the promotion stage
than in the sham operated control liver, and there was no de-
crease in the level of Smad7 transcripts during the later steps
of the promotion, as occurred for TRG1, Smad2, and Smad4
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Fig. 4. Immunohistochemical staining for Smad2. Smad2-positive cells increases with time, 7 days after partial hepatectomy (PH) (A), and
28 days after PH (B) in preneoplastic lesions. Decreased Smad2 in hyperplastic nodules is seen 56 days after PH (C). Smad2 is localized to
the cytoplasm of preneoplastic hepatocytes (D). Magnification at×100 for A, B and C, and at×200 for D.Smads in Preneoplastics Lesion of Rat Liver 515
(Fig. 2).
Expression and Localization of TGR1, Smads Proteins
in Preneoplastic Lesions of the Rat Liver
To investigate the temporal expression and localization of
TGR1, Smad2, Smad4, and Smad7 proteins during the pro-
motion stage of chemical hepatocarcinogenesis, we performed
immunohistochemistry in each liver sample taken from 1, 3,
7, 14, 28, 42, and 56 days after partial hepatectomy. Seven Days
after partial hepatectomy, some TGR1 positive cells were noted
in the preneoplastic lesions, and the adjacent liver parenchy-
ma was either weakly positive or negative (Fig. 3A). With the
lapse of time, the number of positive cells increased in the pre-
neoplastic lesions, which presented as altered cellular foci and
hyperplastic liver nodules (Fig. 3B). Forty two days after par-
C D
A B
Fig. 5. Immunohistochemical staining for Smad4. Smad4-positive cells increase with time, 14 days (A) and 28 days after PH (B) in preneoplastic
lesions. A few positive cells are seen in hyperplastic nodules 42 days after PH (C). Smad4 is localized to the cytoplasm of preneoplastic hepa-
tocytes (D). Magnification at ×100 for A, B and C, and at ×200 for D.
Day after partial hepatectomy
Table 2. Distribution of TGR1 and Smads-positive hepatocytes during chemical hepatocarcinogenesis of the rat
TGR1* ACF 0.0±0.0 0.5±0.1 0.8±0.1 1.2±0.2 1.7±0.1 1.8±0.4 1.5±0.5 0.2±0.1
HN 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 2.8±0.4 1.8±0.5 0.5±0.1
Smad2* ACF 0.0±0.0 0.7±0.2 0.8±0.3 1.1±0.3 2.5±1.0 2.8±0.4 1.5±0.5 0.2±0.1
HN 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 3.0±0.0 4.0±0.2 2.5±0.5 0.4±0.1
Smad4* ACF 0.0±0.0 0.5±0.2 0.7±0.4 1.0±0.2 1.5±0.2 3.2±0.4 1.7±0.5 0.3±0.1
HN 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 4.5±0.4 2.7±0.5 0.7±0.1
Smad7* ACF 0.0±0.0 0.4±0.2 0.8±0.3 1.3±0.2 2.0±0.4 2.8±0.4 3.7±0.5 4.5±0.1
HN 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 2.5±0.0 3.8±0.4 7.7±0.5 12.5±0.1
S 1 3  7 14  28  42 56
Values presented are percent of TGR1 and Smads-positive cells to total nuclei and Means±SD.
S; sham operated control liver, ACF; altered cellular foci, HN; hyperplastic nodule. *Significance difference between each experimental point
(p<0.05).516 D.Y. Park, C.H. Lee, M.Y. Sol, et al.
tial hepatectomy, the numbers of TGR1 positive cells were
reduced (Fig. 3C) (Table 2). TGR1 positive cells were main-
ly hepatocytes, especially in preneoplastic lesions. TGR1 expres-
sion was mainly found in the cytoplasm of hepatocytes with-
out linear reinforcement (Fig. 3D). Smad2 and Smad4 proteins
showed similar expression patterns (Table 2); during the early
C D
A B
Fig. 6. Immunohistochemical staining for Smad7. Significant increases of Smad7-positive cells are noted with time, 7 (A), 28 (B), and 42 days
after PH (C). Smad7 is localized to the cytoplasm of preneoplastic hepatocytes (D). Magnification at ×100 for A, B and C, at ×200 for D.
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Fig. 7. Sequential changes in the TUNEL-positive apoptotic cells. TUNEL-positive cells increased with time and more numerous in the adja-
cent liver parenchyme than the preneoplastic lesion (A). The values shown are mean±SD from measurement upon randomly selected
separate preneoplastic lesions (open bar) and adjacent liver parenchyme (solid bar). S, P, and L indicates the sham operated control liver,
preneoplastic lesions, and adjacent liver parenchyme, respectively.
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steps, positive cells increased in altered cellular foci and hyper-
plastic nodule and with the passage of time their numbers
reduced. Scattered positive cells were also observed around the
preneoplastic lesions (Fig. 4A, C and Fig. 5A, C). The expres-
sions of Smad2 and Smad4 were mainly located in the cyto-
plasm of hepatocytes (Fig. 4D and 5D). Interestingly, Smad7
protein was strongly expressed in altered cellular foci and hyper-
plastic nodules, and positive cells were markedly increased with
the increase with time (Fig. 6A, B). There was no decrease of
Smad7 protein during the later steps of the promotion stage
(Fig. 6C) (Table 2). Some scattered Smad7 positive cells were
also observed around the preneoplastic lesions. The expression
of Smad7 was mainly found in the cytoplasm of hepatocytes
(Fig. 6D).
Sequential Quantification of TUNEL-positive Cells in
Preneoplastic Lesions of Rat Liver
Sequential quantification of TUNEL-positive apoptotic cells
showed that apoptotic cells increased with time and more nu-
merous in the adjacent liver parenchyma than in the preneo-
plastic lesions during promotion stage of chemical hepatocar-
cinogenesis of the rat (p<0.05) (Fig. 7).
DISCUSSION
One notable observation made in this study was the decrease
of TGR1, Smad2 and Smad4 expressions and the increase of
Smad7 expression with time during the promotion stage of
rat hepatocarcinogenesis. This finding suggests that the dys-
regulation of downstream effectors of TGF- may contribute
to the progression of preneoplastic lesions in chemical hepa-
tocarcinogenesis in the rat. The TGF- signaling pathway is
a central component of the mechanisms that control cell pro-
liferation and apoptosis in the liver (18). The disruption of
TGF- signaling at the pre-receptor, receptor, and post-recep-
tor levels that occurs can cause dysregulation of apoptosis and
result in hepatocarcinogenesis in mice (19), rats (20-22), and
humans (23, 24). These reports suggest that the resistance to
the growth inhibitory and apoptotic effects of TGF- are large-
ly due to the loss of TGF- receptors in hepatocellular carcino-
mas and in preneoplastic lesions of the liver. However, little
is known of the involvement of Smads in the regulation of the
TGF- signaling pathway in liver cells and the possible dis-
ruption of these genes during hepatocarcinogenesis. Never-
theless, the impact that Smad genes have on both growth inhi-
bition and apoptosis suggests that these genes may play a sig-
nificant role in hepatocarcinogenesis. In our study, the down-
regulations of TGR1, receptor activated Smad2 and common-
mediated Smad4 were evident during the late promotion stage
of chemical hepatocarcinogenesis. We thought that the down
regulation of TGR1, Smad2, and Smad4 might be a means
of resisting the anti-proliferative effects of TGF- . However,
the precise mechanisms of the down-regulation of TGR1 and
Smads in preneoplastic lesions of rat liver are not known. Some
studies have reported that several mutations of signaling mole-
cules, including TGF- family members, their receptors, or
Smad genes might be evidences for disrupted signaling in many
cancers, such as human and rat hepatocellular carcinomas (25,
26). Mutations of the Smad2-, and Smad4-enconding gene
sequences, but not those of Smad3 or the inhibitory Smad6
or Smad7, have been detected in several carcinomas, but over-
all, are uncommon (27, 28). These observations suggest that
some Smads act as tumor suppressors in carcinogenesis. Tumor-
associated mutations in Smad2 and Smad4 occur most frequent-
ly in the MH2 domain, which mediates heteromeric complex
formation and transcriptional activation (29, 30). Taken togeth-
er, the down-regulation of TGR1, Smad2, and Smad4 might
contribute to the expansion of preneoplastic lesions of rat liver.
However, exact molecular mechanisms of such down regu-
lation remain to be elucidated. In our study, increased Smad7
expression was seen during the promotion stage of chemical
hepatocarcinogenesis in the rat. The increase of inhibitory sm-
ads, such as Smad6 and Smad7 might contribute to the pro-
gression of preneoplastic lesions in chemical hepatocarcino-
genesis in rats by reducing the ability of TGF- to inhibit
their growth. This contention is in agreement to the finding
that the endogenous TGF- -mediated induction of Smad7
resulted in a higher ‘‘threshold’’ requirement for the anti-
proliferative signals mediated by receptor-regulated Smads,
and might be involved in reduced responsiveness to cytokines
in some human hepatocellular carcinoma cells (29). Also,
enhanced Smad7 levels, as observed in pancreatic carcinomas,
may decrease Smad responsiveness (30). Increased expressions
of Smad6 and Smad7 have been described in human pancreat-
ic and rat prostatic carcinoma (30-32). Therefore, we suggest
that inhibitory Smads, such as Smad7, may be involved in the
progression of preneoplastic lesions in rat liver by inducing
resistance to apoptotic death by TGF- .
To investigate the role of TGR1 and Smads in hepatocar-
cinogenesis, the sites of their expressions and temporal nature
of their expressions should be determined as a first step. In our
study, in the early steps of the promotion stage of chemical
hepatocarcinogenesis, TGR1, Smad2, Smad4 and Smad7 pos-
itive cells were observed to increase in preneoplastic lesions, and
subsequently, TGR1, Smad2 and Smad4 positive cells decreased
coincidentally with result of RT-PCR. However, Smad7 pos-
itive cells did not decrease with time, and immunohistochem-
istry revealed that hepatocytes of preneoplastic lesions of rat
liver were the main site of TGR1, Smad2, Smad4 and Smad7
expression. It is tempting to speculate, therefore, that the expr-
essions of TGR1, Smad2, and Smad4 in hepatocytes of pre-
neoplastic lesions, especially during the early times of the pro-
motion stage, might contribute to the removal of genetical-
ly unaltered hepatocytes. In addition, the decreased expres-
sions of TGR1, Smad2, Smad4, and the increased expression
of Smad7 during the late times of the promotion stage might518 D.Y. Park, C.H. Lee, M.Y. Sol, et al.
contribute to the secondary expansion of preneoplastic lesions,
by the decreased apoptosis of the preneoplastic genetically
altered hepatocytes. This contention is in agreement to a study
which found that the clonal expansion of genetically altered
hepatocytes occurs during the stage of carcinogenic promotion,
and this expansion is caused by a selective increase in cell pro-
liferation and a selective decrease in the apoptosis of preneo-
plastic genetically altered hepatocytes (33). However, our study
demonstrated that apoptotic cells increased with time. These
findings suggest that different apoptosis signaling pathways
other than TGF- signaling pathway, such as Fas/ Fas ligand
pathway, might have significant roles in chemical hepatocar-
cinogenesis of rat, especially late times of promotion stage (34).
Also, our study showed that apoptotic cells are more numer-
ous in adjacent liver parenchyme than in preneoplastic lesions.
These findings suggested that expansion of preneoplastic lesions
were partially accelerated by apoptosis of adjacent liver paren-
chyma. This contention is in agreement with a study which
found that hepatoma cells might generate TGF- -mediated
peritumoral apoptosis of hepatocytes in a paracrine manner,
which could facilitate their expansion in situ (35).
In addition, immunohistochemical studies have revealed
variations in Smad expression in different tumors. For exam-
ple, the expressions of Smad2 and Smad3 were decreased in
the epithelial components of human skin and in rat prostatic
carcinomas (31, 36), while in colorectal tumors these expres-
sions reported to be increased (37). The mechanisms under-
lying these changes in Smad expressions are unknown, alth-
ough a recent study (38) showed that certain mutations in
Smad2 and Smad4 found in human cancers could selectively
target these mutant proteins for ligand-independent ubiqui-
tin-mediated proteosomal degradation through the UbcH5
family of E2 ligases, in effect silencing protein expression. How-
ever, more in vitro and in vivo study is needed to confirm these
findings. Taken together, we suggest that dysregulation of the
downstream effectors of TGF- , such as TGR1, Smad2, Smad4
and Smad7 might contribute to the progression of preneoplas-
tic lesions in the chemical hepatocarcinogenesis of the rat.
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